Literature DB >> 11851905

Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough.

M G Rumi1, F De Filippi, M F Donato, E Del Ninno, M Colombo.   

Abstract

In short-term studies, patients with chronic hepatitis C virus (HCV) infection, consistently normal serum aminotransferase (ALT) levels, and minimal or mild necro-inflammatory changes in the liver, did not progress to histologically severe hepatitis. There are no data on longer term outcome of liver disease in these patients. We describe two patients with HCV infection (genotype 2c) with a rise in serum ALT values greater than 10 times the upper normal value that occurred after an 8- and 15-year period of persistently normal or minimally elevated ALT levels. In both patients, the rise in ALT values lasted more than 16 weeks and was not associated with any symptom or risk factor for acute hepatitis. A liver biopsy performed 4 and 18 months after the ALT flare showed clear-cut progression from chronic hepatitis with mild activity to chronic hepatitis with severe activity and central to portal septal fibrosis (Ishak score: grading 14 and 6; staging: 4 and 5, respectively). Hence, extended surveillance of HCV carriers with consistently normal or minimally elevated ALT values is warranted as these patients are at risk of ALT flares and may develop progressive liver disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11851905     DOI: 10.1046/j.1365-2893.2002.00328.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  HCV genotype 2 as a risk factor for reactivation of chronic HCV infection.

Authors:  N Coppola; L M Vatiero; E Sagnelli
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

2.  Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.

Authors:  M G Rumi; F De Filippi; C La Vecchia; M F Donato; S Gallus; E Del Ninno; M Colombo
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels.

Authors:  Hitoshi Tajiri; Yuri Etani; Sotaro Mushiake; Yasuhiro Hasegawa; Keiichi Ozono
Journal:  Eur J Pediatr       Date:  2006-10-28       Impact factor: 3.183

4.  Treatment of chronic hepatitis C in a patient affected by systemic sclerosis.

Authors:  Guido Poggi; Laura Villani; Federico Sottotetti; Barbara Tagliaferri; Benedetta Montagna; Alessio Amatu; Giovanni Bernardo
Journal:  Gastroenterol Res Pract       Date:  2009-11-17       Impact factor: 2.260

5.  Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients.

Authors:  Liliana S C Mendes; Marcelo E Nita; Suzane K Ono-Nita; Evandro S Mello; Luiz Caetano da Silva; Venancio A F Alves; Flair J Carrilho
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

6.  Pathological evolution of hepatitis C virus-"Healthy carriers".

Authors:  Rodolphe Sobesky; Pascal Lebray; Bertrand Nalpas; Anais Vallet-Pichard; Helene Fontaine; Jean-Luc Lagneau; Stanislas Pol
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

7.  The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.

Authors:  Marcello Persico; Savino Bruno; Andrea Costantino; Marta Mazza; Piero Luigi Almasio
Journal:  Int J Hepatol       Date:  2011-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.